Helaina Series B nets $45 million for human lactoferrin bioactive
In New York, biotech company Helaina has raised $45 million to develop and scale human equivalent-bioactive proteins produced via precision fermentation. The Series B funding brings the company’s total equity funding to $83 million and was led by Avidity Partners. Spark Capital, Ingeborg Investments, Tom Williams of Heron Rock, Barrel Ventures, Siam Capital, Relish Works, […]
